Biomica is a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics for the treatment of immune-mediated and infectious diseases, with specific focus on Immuno-Oncology and GI related disorders.

The company aims to identify and target microbes, metabolites and other microbiome-related components that are key in the etiology of human diseases impacted by the microbiome, using both biological and small-molecule approaches.

Biomica’s discovery and development efforts are powered by PRISM (Predictive, high Resolution, Integrative Selection of Microbes) platform. PRISM is a proprietary metagenomics analysis platform for functional genomics profiling utilizing internal comprehensive databases. Employing Biomica’s drug discovery approach, PRISM combines a profound understanding of the microbiome and its functions and their intricate relations with the human host.

Biomica is a subsidiary of Evogene.